Skip to main content

Table 1 Characteristics of insured patients initiating PEG-IFN-alfa and ribavirin treatment for chronic HCV infection

From: Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study

Characteristic No. (%) of insured patients (n = 1269)
Age, mean (SD), y 50.2 (7.7)
Age group (y)  
18-29 31 (2.4)
30-39 61 (4.8)
40-49 405 (31.9)
50-59 675 (53.2)
60-69 91 (7.2)
70+ 6 (0.5)
Female 459 (36.2)
Region  
East 123 (9.7)
Midwest 242 (19.1)
South 705 (55.6)
West 199 (15.7)
Type of health benefits  
Commercial 1,244 (98.0)
Medicaid-HMO 25 (2.0)
HIV/AIDS 44 (3.5)
  1. AIDS, acquired immune deficiency syndrome; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PEG-IFN-alfa, pegylated interferon alpha.